A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold

Two China-Discovered Cancer Treatments May Win US FDA Approval This Year

 
• By Alaric DeArment

Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.

China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
While it's early days, Chinese drug makers are off to a strong start in gaining a foothold in the US market • Source: Shutterstock

More from China

More from Focus On Asia